Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Evacetrapib Tablets with Varying Particle Sizes
NCT02497391Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evacetrapib in hypercholesterolemia (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration and Area Under the Concentration Versus Time Curve From Zero to Infinity. Started Jul 2015; status: completed.
02
Drugs
evacetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02497391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497391.